Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

SAN FRANCISCO, March 12, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2024.Cash and investments in marketable securities on December 31, 2024 were $269.1 million as compared to$329.4 million at December 31, 2023. Nektar's cash and marketable securities are expected to support strategic development activities and operations into the fourth quarter of 2026."The significant progress we made last year in advancing our immunol ...